Anupam Rasayan records Rs 1,022.394 crore provisional goodwill

Anupam Rasayan India Limited recognised Rs 1,022.394 crore of provisional goodwill after gaining control of Bliss GVS Pharma Ltd. through a 50.07% holding, with the acquiree’s profit included in consolidated results from the acquisition date to September 30, 2026. Valuations required for the purchase-price allocation remain in progress.

What stake did Anupam Rasayan acquire in Bliss GVS Pharma?

Anupam Rasayan acquired 50.07% of Bliss GVS Pharma’s paid-up equity share capital through its own purchases and purchases by wholly owned subsidiary Mates Visa Consultancy Pvt. Ltd. The transaction followed a share purchase agreement dated May 23, 2026 and an open offer under the Securities and Exchange Board of India’s 2011 takeover regulations.

Mates Visa acquired 47.95% as a person acting in concert, while Anupam Rasayan acquired 2.12% directly through the open offer or open-market purchases. The filing states that Anupam Rasayan became Bliss GVS Pharma’s ultimate parent company and promoter from the acquisition date. It does not disclose the consideration paid for the 50.07% holding.

The September 30, 2026 consolidation perimeter identifies Bliss GVS Pharma and its subsidiaries as subsidiaries of Mates Visa, while Mates Visa is a wholly owned subsidiary of Anupam Rasayan. This differs from an associate relationship in the same filing, where Tangent Science Private Limited is identified as an associate of Jainam Intermediates Private Limited.

How has Anupam Rasayan included Bliss GVS Pharma in its accounts?

Anupam Rasayan has included Bliss GVS Pharma’s profit from the acquisition date through September 30, 2026 in its consolidated results. The filing does not separately disclose Bliss GVS Pharma’s revenue, profit after tax, assets, liabilities or cash-flow contribution for either the September quarter or the half year.

Consolidated revenue from operations was Rs 805.935 crore for the quarter ended September 30, 2026, compared with Rs 731.398 crore in the corresponding quarter of 2025. Consolidated profit after tax was Rs 64.969 crore, compared with Rs 57.152 crore a year earlier, but the filing does not attribute either year-on-year movement specifically to Bliss GVS Pharma.

For the half year ended September 30, 2026, revenue from operations rose to Rs 1,460.915 crore from Rs 1,217.225 crore in the comparable 2025 period, while profit after tax increased to Rs 116.183 crore from Rs 105.609 crore. Since the acquiree is included only from its acquisition date, these comparisons combine the acquired business with Anupam Rasayan’s pre-existing operations.

Why is the Rs 1,022.394 crore goodwill provisional?

The Rs 1,022.394 crore goodwill is provisional because valuations of certain identifiable intangible assets, property, plant and equipment, and related deferred taxes are under process. Anupam Rasayan recognised the amount under Indian Accounting Standard 103, Business Combinations, pending completion of the purchase-price allocation within the applicable measurement period.

The filing does not state the consideration transferred for Bliss GVS Pharma, the fair values assigned to the acquiree’s identifiable assets and liabilities, or the final goodwill amount after valuation work is completed. As a result, the Rs 1,022.394 crore balance is subject to revision as the valuations of identified assets and related deferred taxes are finalised.

Reported consolidated goodwill was Rs 1,693.565 crore at September 30, 2026, against Rs 663.461 crore at March 31, 2026. The Rs 1,030.104 crore increase is close to, but not the same as, the provisional goodwill recorded for Bliss GVS Pharma, so the filing indicates that other acquisition or consolidation movements also affected the total goodwill balance.

How did consolidation change Anupam Rasayan’s balance sheet?

Anupam Rasayan reported total consolidated assets of Rs 11,394.890 crore at September 30, 2026, up from Rs 8,012.604 crore at March 31, 2026. Non-current assets increased to Rs 6,214.352 crore from Rs 4,285.096 crore, including the acquisition-related goodwill recognised within intangible assets.

Non-controlling interest rose to Rs 2,148.391 crore from Rs 1,328.122 crore over the six months to September 30, 2026. The filing does not provide a company-by-company reconciliation of this increase, including the portion related to Bliss GVS Pharma’s shareholders outside the group’s controlling interest.

The half-year cash-flow statement reported Rs 1,687.230 crore under “adjustment due to consolidation” in investing activities. Net cash used in investing activities was Rs 2,317.855 crore for the half year ended September 30, 2026, compared with Rs 253.163 crore used in the prior-year period; the statement does not identify the consolidation adjustment as acquisition consideration.

Which acquisition-accounting matters remain unresolved?

Anupam Rasayan expects to finalise the Bliss GVS Pharma purchase-price allocation within the measurement period permitted by Indian Accounting Standard 103. Until the valuations of intangible assets, property, plant and equipment, and deferred taxes are completed, the recorded Rs 1,022.394 crore goodwill and related asset allocation remain provisional.

The filing says the group also expects to finalise the purchase-price allocation for Jayhawk Fine Chemicals Corporation, acquired effectively from February 27, 2026, within the applicable measurement period. It does not quantify provisional goodwill for Jayhawk Fine Chemicals Corporation in the September 30, 2026 announcement.

The reporting perimeter changed in other ways during the period. Monitchem Kansas S.à.r.l was liquidated effective June 30, 2026 and its half-year financial information was incorporated in its parent entity, while Tanfac Industries Limited allotted 260,065 equity shares to Anupam Rasayan on September 9, 2026 under a preferential allotment.

Conclusion

The acquisition has made Bliss GVS Pharma part of Anupam Rasayan’s controlled group through a 50.07% holding, while adding Rs 1,022.394 crore of provisional goodwill. The acquiree’s post-acquisition profit is included in the September 30, 2026 consolidated results, alongside higher total assets of Rs 11,394.890 crore.

The next disclosed accounting event is completion of the Bliss GVS Pharma purchase-price allocation within the Indian Accounting Standard 103 measurement period. Investors can watch for final valuations of intangible assets, property, plant and equipment and deferred taxes, which may revise the provisional goodwill, as well as progress on the separate Jayhawk Fine Chemicals Corporation allocation.